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Abstract
Background: Prevalence rates of Hepatitis C Virus (HCV) co-infection, the distribution of HCV genotypes, and the frequency
of spontaneous resolution of hepatitis C in patients infected with the Human Immunodeficiency Virus (HIV) have a
worldwide disparity. The purpose of this study is to investigate the prevalence of HCV antibodies (anti-HCV) in patients with
HIV, the proportion and correlates of infection by different HCV genotypes, and rates of spontaneous resolution of HCV
infection.
Methods: A cross-sectional study was conducted among 1143 HIV patients under follow-up in a HIV/AIDS outpatient
reference center of the Brazilian public health system. From 357 anti-HCV positive patients, a consecutive sample of 227
individuals HCV treatment-naı ¨ve was interviewed and 207 was tested for HCV-RNA and genotypes.
Results: Anti-HCV was detected in 357 patients (31.2%). HCV-RNA was undetectable in 16.4% of 207 anti-HCV positive
individuals. Genotype 1 was diagnosed in 81.5% of the sample, genotype 2 in 1.7% and genotype 3 in 16.2%. Male gender
was the unique characteristic associated with higher prevalence of genotype 1 HCV.
Conclusions: Co-infection by HCV is frequent among patients with HIV in our State, and it is particularly high the infection
by HCV genotype 1. Further investigation is necessary to explain the important regional variation in the proportion of
infection by the different HCV genotypes and to better understand rates of spontaneous HCV clearance.
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Introduction
It has been estimated that 38.6 million people are infected by
the human immunodeficiency virus (HIV) worldwide, and 4–5
million are also infected with hepatitis C virus (HCV) [1]. In
Brazil, about 0.5% of the adult population is infected with HIV [1]
and among those attending the public health services, 16% HIV-
HCV co-infection rate had been reported in outpatient care
centers [2,3], 42% in HIV-HCV anonymous testing centers [4],
and 54% for patients HIV infected in infectious diseases clinics
[5].
The survival of HIV infected patients has markedly improved
since the introduction of highly active antiretroviral treatment
(HAART). [6] While treatment of HIV-HCV co-infected patients
has lower rates of sustained virological response (SVR), it might
also be complicated by adverse effects and drug interaction.
Therefore, the selection of patients with a favorable risk/benefit
ratio to respond to treatment is necessary. The best predictor of
treatment effectiveness is the HCV genotype and, consequently, it
becomes a key factor to support therapeutic decisions. [7–11]
Besides the treatment issues, geographical distribution of HCV
genotypes might help to elucidate new routes of infection among
HIV infected patients.
This study investigated the prevalence of HCV antibodies (anti-
HCV) in patients with HIV, the proportion and correlates of
infection by different HCV genotypes, and rates of undetectable
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atitis C spontaneous resolution).
Methods
Study design
This cross-sectional study was conducted in a public reference
center for HIV testing and treatment in Porto Alegre, southern
Brazil. Patients were referred by primary care doctors or
anonymous testing centers.
The routine protocol for evaluation of patients included
complete medical history and physical examination, basic
hematological and biochemical tests, toxoplasmosis screening test,
PPD skin test, chest X-ray, CD4, HIV viral load, hepatitis B
surface antigen (HBsAg) and hepatitis C antibodies (anti-HCV).
Anti-HCV was performed using third-generation enzyme-linked
immunosorbent assays (ELISA-3 HepanostikaH - BioMerrie).
Participants
A registry of 3490 patients with HIV infection was launched in
1996 in our center, comprising all patients with at least one
appointment with the infectious diseases doctor. All records were
retrieved and the follow-up of surviving participants was updated
until 2006. The eligibility criteria included patients aged 18 years
or older, who had at least one appointment in the previous 12
months and were co-infected by HCV. The final sample
comprised 1143 HIV patients actively under follow-up.
All patients with an anti-HCV positive test were consecutively
interviewed from March-2005 to September-2006, during the
routine visit to the attending physician. Patients who did not
complete the study protocol at that day were re-scheduled to
prevent losses.
Data collection
Interviewers were trained and certified to conduct the data
collection, and quality control was carried out at random by one of
the investigators. Patients were interviewed using a standardized
questionnaire, which included questions pertaining demographic
(gender, age, skin color) and behavioral (alcohol consumption,
tattooing, sharing personal hygiene objects - tooth brushes,
shaving blades, cuticle nippers -, acupuncture) characteristics,
socioeconomic status (family income, schooling), medical history
(blood transfusion, accidental exposure to biological material),
sexual behavior (age at first sexual intercourse, sexual orientation,
anal sex, use of condom, number of sexual partners), and use of
illicit drugs (injecting drugs, snorting cocaine, crack cocaine,
marijuana, solvents/inhalants). Variables associated with HIV
infection (CD4 lymphocyte count, CD4/CD8 ratio, use of
antiretroviral drugs, duration of HIV diagnosis, opportunistic
infections) were also investigated.
After the interview, blood samples were collected and processed
for HCV RNA detection and HCV genotype determination. The
laboratory was certified by the Brazilian Society of Clinical
Pathology and Laboratory Medicine.
HCV RNA detection and genotyping
The real-time polymerase chain reaction (RT-PCR) technique
was used for the qualitative detection of HCV RNA as described
elsewhere [12–14]. Genotypes were identified using the restriction
fragment length polymorphism (RFLP) [15], adapted as described
elsewhere [16]. The lower limit of detection of the test is 50 UI/
mL. All tests were performed in duplicate, and reliability of HCV
RNA was tested in a random sampling of 10% of the patients.
Two thirds of undetectable HCV-RNA patients were retested.
Study variables
The main study outcomes were the detection of HCV
antibodies, defined as a positive result in the anti-HCV test, and
the prevalence of HCV infection according to the genotypes. In
addition, we performed an exploratory analysis on characteristics
associated with spontaneous resolution of HCV infection,
characterized as an undetectable HCV-RNA in an anti-HCV
positive patients who have never been submitted to an interferon
based therapy.
The self-report of skin color was categorized into white or non-
white. Schooling was measured by the number of years at school.
Heterosexual orientation was established for those who reported
sexual intercourse with partners of the opposite sex; man who have
sex with men, as well as women who have sex with women, were
categorized as homosexuals, and bisexuals were defined when they
reported having sex with men and women [17]. Consumption of
alcoholic beverages, smoking and use of illicit drugs were
investigated using standardized questions. CD4, CD8 counts and
HIV viral load, determined closest to the appointment date, were
used in the analysis. Antiretroviral treatment was defined as taking
any medicine at the time of the interview. The duration of HIV
infection was calculated from the date of the diagnosis to the date
of the interview as reported by the patient and confirmed with
medical records.
Statistical analysis
Data were entered in duplicate and checked for consistency and
reliability using the Epinfo 3.3.2 software. The Statistical Package
for the Social Sciences (SPSS, version 14.0, Chicago, Il, USA) was
used for statistical analyses. Pearson chi-square test and analysis of
variance were used to analyze characteristics associated with HCV
RNA and genotypes. P value ,0.05 was considered statistically
significant and a trend toward association was established for p
value .0.05 and ,0.15. Point prevalence and 95% confidence
interval (CI) were presented for HIV-HCV coinfection, HCV
RNA and genotypes. The Institutional Review Board and Ethical
Committee approved the protocol, and all participants gave
informed consent.
Results
Anti-HCV testing was performed in 1143 patients. A positive
anti-HCV test was detected for 357 (31.2%) individuals. From
March-2005 to September-2006, all patients who went to the
routine evaluation were interviewed, resulting in the enrollment of
a consecutive sample of 227 co-infected patients. RNA HCV
testing was performed in 207 patients (Figure 1), as 20 patients
didn’t come to the blood collecting laboratory to be tested. The
comparison between patients with and without HCV-RNA testing
results available did not reveal differences regarding demographic
characteristics.
Table 1 shows that most participants were men, aged on
average 40 years, had white skin color, injecting cocaine users, and
approximately 19% were bisexuals.
Prevalence of HIV-HCV coinfection and HCV genotypes
Figure 1 shows that among 207 HIV-HCV co-infected patients,
according to the anti-HCV test, the infection was confirmed based
on a positive HCV-RNA for 173 (83.6%) participants. No of the
included patients had been submitted to antiviral therapy for
HCV.
Genotype 1 HCV was the most prevalent (81.5%; 95%CI 75.7–
87.3), followed by genotype 3 (16.2%; 95%CI 10.7–21.7), and only
two cases had genotype 2 (1.7%; 95%CI 0–3.6). Genotypes 4, 5
HCV-HIV Co-Infection in Brazil
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determined in one patient.
Characteristics associated with HCV genotypes
Table 2 shows that most characteristics were not significantly
associated to the genotype, except higher prevalence of genotype 1
among men. There was a trend toward an association with
transfusions in the past. Patients with genotype 1 were more likely
to be on antiretroviral treatment and have longer duration of HIV
infection than genotype 3. Also, a trend for a lower HIV viral load
in patients infected with HCV genotype 3 compared to 1 was
found. (Table 3)
Characteristics of HCV RNA negative patients
Thirty four patients (16.9%) had negative HCV RNA test.
Undetectable HCV RNA was more frequent among those who
102 individual who reported sharing of personal hygiene objects
(22.0% vs.10.8%; P=0.03). The prevalence of undetectable HCV
RNA levels was high among homosexuals (45.5%), intermediate
between heterosexuals (16.7%) and reduced for bisexuals (7.7%)
(P=0.01).
Discussion
This study detected high prevalence of individuals co-infected
with HCV (31.2%) among patients with HIV in our State. It was
similar to the described in the United States (31–36%) [18,19] for
patients under follow-up at infectious diseases clinics and to that
reported for volunteers of a multicenter trial conducted mainly in
Europe (31%) [20]. This prevalence was higher than those
reported in public health services for HIV patients from the North
(16%) and Southeast (18%) of Brazil [3]. Since HIV and HCV are
transmitted by large or repeated exposures to infected blood, the
difference in prevalence of co-infection among regions or countries
might vary according to the distribution of risk factors, noticeably,
injecting drug use [21]. In countries with no remarkable variation
on IDU prevalence across regions, other risk factors such as
sharing personal hygiene objects may play a major role [22].
The genotype 1 prevalence of 81.4% was higher than previously
described among individuals infected (50.9%) [23] and non-
infected with HIV (50%) in Brazil. [23–25] However, participants
of those studies were referred to the specialist for evaluation and
treatment of hepatitis C. Differently from studies in which an
evaluation by a gastroenterologist or a clinical trial are the source
of enrollment, patients from our study were withdraw from a
broad spectrum of HIV infected patients, and this may account for
a sample of HIV-HCV coinfected individuals that better
represents the true genotype distribution in our setting. World-
wide, genotype 1 prevalence in patients co-infected by the HIV-
HCV also showed a large variation: from 26% in China [26], to
53 to 75% in Spain [27,28], and to 87% in United States [29].
The high prevalence of genotype 1 has been associated to the
transmission of HCV by injecting drug use [21] which accounted
for approximately 22-fold increase the risk of co-infection, in this
population. [22] Genotypes 4, 5 and 6 HCV were not detected,
which is in accordance with other reports. [23–25,30]
The only demographic variable associated to HCV genotype
was male sex. The prevalence of males was greater among
genotype 1 carriers than among genotype 3 patients. The reasons
for this difference are not completely understood, and, our sample
are not enough large (97 males with genotype 1 and 12 with
genotype 3) to explore this finding in a more detailed basis. Small
epidemiological differences that didn’t reach statistical significance
in our study, such as rates of illicit drug use, blood transfusion, and
sexual behavior, may be the link to this finding when taken
together. We have no reason to believe males or females are
biologically prone to contract a specific HCV genotype. Instead,
we believe that epidemiological circumstances exposed man or
woman to the genotype they became infected. Our data suggest
small differences in characteristics associated with HIV according
to HCV genotypes. The only data witch presented statistically
significant difference was the higher antiretroviral use among
HCV genotype 1 compared to genotype 3 patients. The trends of
a higher time since HIV diagnosis and higher prevalence of HIV
Figure 1. HCV-HIV prevalence and genotype distribution.
Flowchart of inclusion in the different stages of the study, and patient’s
prevalence of anti-HCV positive, HCV-RNA positive and HCV genotypes.
doi:10.1371/journal.pone.0010494.g001
Table 1. Characteristics of HIV infected patients with anti-
HCV positive test (N=227).
N (%) or mean ±SD
Male gender (%) 143 (63%)
Age (years) 40.368.7






Transfusion before 1993 24 (10.6)
Use of illicit drugs
Marijuana 148 (65.2)
Inhaled cocaine 138 (60.8)
Injecting 127 (55.9)
Crack cocaine 62 (27.3)
CD4 (cells/mm
3) 3876217
Duration of HIV diagnosis (years) 6,064.5
doi:10.1371/journal.pone.0010494.t001
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probably related one to another, since the longer the time since
HIV diagnosis, greater are the chances of antiretroviral treatment
and, once one treatment, greater the chances of achieving
undetectable HIV viral load. Data regarding association between
HCV genotypes and HIV characteristics are scarce. Our data are
in accordance with data already published by Soriano et al. [31]
The EuroSIDA study authors reported higher antiretroviral use
among HCV genotype 1 than genotype 3 infected patients. They
also found no CD4 cell count and HIV viral load difference
according to HCV genotype. [31]
Few studies have investigated systematically the prevalence of
co-infection by HCV-RNA in patients with HIV infection. In the
EuroSIDA less than 10% of the individuals with anti-HCV
positive results had the infection confirmed by HCV-RNA
detection [20]. In this study, high rate of patients (91.2%) were
tested for HCV-RNA using real time-PCR technique, and a
sample of negative and positive tests (40%) were repeated in order
to reassure reproducibility. In a multi-center study, conducted in
Europe and Australia, only 63% of patients with anti-HCV
positive results underwent to HCV-RNA test, and 82% had a
positive result [32]. None of the patients included in the study had
been exposed to HCV treatment previously to the interview, and a
false negative PCR result is unlikely since the HCV-RNA
detection technique has high sensitivity [33] and all samples were
processed in duplicates. Therefore, it is likely that participants with
anti-HCV without detectable HCV viremia (16%) had spontane-
ous resolution of the infection. Several factors have been associated
with spontaneous resolution of HCV viremia, such as cell immune
responses [34–36], Asian or African ethnicity [37], and parenteral
exposure to the virus [38]. Spontaneous resolution would be lower
in individuals co-infected with HIV. [34] This study was not
designed with enough power to investigate factors associated to
spontaneous resolution. We hypothesize that individuals who have
Table 2. Characteristics of patients coinfected with HIV-HCV according to HCV genotype [N (%) or mean 6SD].
Total* Genotype 1 Genotype 3 P
N=173 N=141 N=28 Value
Male sex 111 (64.2) 97 (68.8) 12 (42.9) 0.009
Age (years) 40.168.9 40.168.7 40.3610.2 0.9
White skin color 96 (55.5) 78 (55.3) 18 (64.3) 0.4
Schooling (years) 6.663.5 6.663.4 6.763.6 0.3
Sexual orientation 0.6
Heterosexual 131 (75.6) 104 (73.8) 23 (82.1)
Homosexual 6 (3.5) 5 (3.5) 1 (3.6)
Bisexual 36 (20.9) 32 (22.7) 4 (14.3)
Transfusion before 1993 20 (11.6) 19 (13.5) 1 (3.6) 0.14
Illicit drug use
Marijuana 119 (68.8) 102 (72.3) 15 (53.6) 0.5
Snorting cocaine 112 (64.7) 94 (66.7) 16 (57.1) 0.3
Injecting 103 (59.5) 86 (61.0) 15 (53.6) 0.5
Crack 50 (28.9) 40 (28.4) 8 (28.6) 1.0
*total number of patients includes 3 cases of genotype 2 and 1 of undetermined genotype.
doi:10.1371/journal.pone.0010494.t002
Table 3. Characteristics associated with HIV according to HCV genotype [N (%) or mean6SD].
Total* Genotype 1 Genotype 3 P value
N=173 N=141 N=28
CD4 (cells/ml) 0.9
#200 28 (15.9) 23 (16.3) 4 (14.3)
201–350 63 (36.5) 52 (36.9) 9 (32.1)
.350 82 (47.6) 65 (46.1) 14 (50.0)
CD8 (cells/ml) 11186903 11476980 9556320 0.6
CD4/CD8 ratio 0.4860.47 0.4960.50 0.4860.29 0.9
HIV viral load ,50 copies/ml 69 (39.9) 60 (42.6) 8 (28.6) 0.2
Use of antiretroviral drug 141 (81.5) 119 (84.4) 19 (67.9) 0.04
Time since HIV diagnosis (years) 5.463.9 5.663.9 4.563.3 0.1
*total number of patients includes 3 cases of genotype 2 and 1 of undetermined genotype.
doi:10.1371/journal.pone.0010494.t003
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transmission by sharing personal hygiene objects, were more likely
of having spontaneous resolution. HCV alternative routes of
transmission, like sharing personal hygiene objects, are matter
of controversy. Probably, small amounts of blood present in
tooth brushes, shaving blades and cuticle nippers could explain
HCV transmission in patient without other major risk factors.
[18,22,39–42]. This hypothesis should be better investigated in
future studies designed specifically to study HCV transmission routes.
In conclusion, HCV co-infection is frequent among patients
with HIV infection in our State, and the genotype 1 prevails. A
small proportion of patients present spontaneous resolution of the
infection by HCV. The higher proportion of infection by the
difficult-to-treat HCV genotype 1 has important consequences for
the public health system.
Acknowledgments
The authors thank the personnel staff, physicians and patients of the
Hospital Sanato ´rio Partenon, Therapeutic Assistance Service, for their
collaboration to make this study possible; and Simbios Biotecnologia for
performing the high quality molecular biology tests.
Preliminary data on this study was presented at: 14
th United European
Gastroenterology Week–Berlin, Germany–2006. Abst WED-G-20. Gut
2006; 55 (suppl V): A249.
Author Contributions
Conceived and designed the experiments: FHW SCF NTB ABdMB FDF.
Performed the experiments: FHW NTB PRA MLRI MF. Analyzed the
data: FHW SCF NTB PRA MLRI ABdMB FDF. Contributed reagents/
materials/analysis tools: FHW PRA MLRI MF. Wrote the paper: FHW
SCF NTB ABdMB FDF.
References
1. UNAIDS. Global Report 2006. Avaiable at: http://data.unaids.org/pub/
GlobalReport/.
2. Monteiro MR, do Nascimento MM, Passos AD, Figueiredo JF (2004) Hepatitis
C: prevalence and risk factors among patients with HIV/AIDS in Belem Para, in
Brazilian Amazon. Rev Soc Bras Med Trop 37(Suppl 2): 40–6.
3. Mendes-Correa MC, Barone AA, Guastini C (2001) Hepatitis C virus
seroprevalence and risk factors among patients with HIV infection. Rev Inst
Med Trop Sao Paulo 43: 15–9.
4. Pereira GA, Stefani MM, Martelli CM, Turchi MD, Siqueira EM, et al. (2006)
Human immunodeficiency virus type 1 and hepatitis C virus co-infection and
viral subtypes at an HIV testing center in Brazil. J Med Virol 78: 719–23.
5. Pavan MH, Aoki FH, Monteiro DT, Gonc ¸ales NS, Escanhoela CA, et al. (2003)
Viral hepatitis in patients infected with human immunodeficiency virus.
Braz J Infect Dis 7: 253–61.
6. Merchante N, Giron-Gonzalez JA, Gonzalez-Serrano M, Torre-Cisneros J,
Garcı ´a-Garcı ´a JA, et al. (2006) Survival and prognostic factors of HIV-infected
patients with HCV-related end-stage liver disease. AIDS 20: 49–57.
7. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, et al. (2004)
Pegylated interferon alpha-2b vs standard interferon alpha-2b, plus ribavirin, for
chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
JAMA 292: 2839–48.
8. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcı ´aJ ,
et al. (2004) Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus
infection in HIV-infected patients. N Engl J Med 351: 438–450.
9. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, et al. (2004)
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for
chronic hepatitis C in HIVcoinfected persons. N Engl J Med 2004; 351: 451–9.
10. Laguno M, Murillas J, Blanco JL, Martı ´nez E, Miquel R, et al. (2004)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus
ribavirin for treatment of HIV/HCV co-infected patients. AIDS 18: F27–F36.
11. Koziel MJ, Peters MG (2007) Viral hepatitis in HIV infection. N Engl J Med
356: 1445–54.
12. Boom R, Sol CJ, Salimans MM, Wertheim-van Dillen PM, van der Noordaa J
(1990) Rapid and simple method for purification of nucleic acids. J Clin
Microbiol 28: 495–503.
13. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, et al. (1994) A
proposed system for the nomenclatute of hepatitis C viral genotypes. Hepatology
19: 1321–4.
14. Sanguinetti CJ, Dias Neto E, Simpson AJ (1994) Rapid silver staining and
recovery of PCR products separated on polyacrylamide gels. Biotechniques 17:
914–21.
15. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, et al. (1994) Geographical
distribution of hepatitis C virus genotypes in blood donors: an international
collaborative survey. J Clin Microbiol 32: 884–92.
16. Fonseca ASK, Lunge VR, Ikuta N (1999) New genotype of hepatitis C virus
(HCV) in Brazil. In: XX World Congress of Pathology and Laboratory
Medicine, Sa ˜o Paulo. pp 69–74.
17. Barcellos NT, Fuchs SC, Fuchs FD (2003) Prevalence of and risk factors for HIV
infection in individuals testing for HIV at counseling centers in Brazil. Sex
Transm Dis 30: 166–73.
18. Bollepalli S, Mathieson K, Bay C, Hillier A, Post J, et al. (2007) Prevalence of
Risk Factors for Hepatitis C Virus in HIV-Infected and HIV/Hepatitis C Virus-
Coinfected Patients. Sex Transm Dis34: 367–70.
19. Sherman KE, Rouster SD, Chung RT, Rajicic N (2002) Hepatitis C Virus
Pravalence among Patients Infected with Human Immunodeficiency Virus: A
Cross-Sectional Analysis of the US Adult AIDS Clinical Trial Group. Clin Infec
Dis 34: 831–7.
20. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, et al. (2005)
Influence of hepatitis C virus infection on HIV-1 disease progression and
response to highly active antiretroviral therapy. J Infect Dis 192: 992–1002.
21. Alter MJ (2006) Epidemiology of viral hepatitis and HIV co-infection. J Hepatol
44: S6–S9.
22. Wolff FH, Fuchs SC, Barcellos NT, Falavigna M, Cohen M, et al. (2008) Risk
factors for hepatitis C virus infection in individuals infected with the HIV. Dig
Liver Dis 40: 460–7.
23. Valle Tovo C, Alves de Mattos A, Ribeiro de Souza A, Ferrari de Oliveira
Rigo J, Lerias de Almeida PR, et al. (2007) Impact of human immunodeficiency
virus infection in patients infected with the hepatitis C virus. Liver International
27: 40–6.
24. Krug LP, Lunge VR, Ikuta N, Fonseca AS, Cheinquer H, et al. (1996) Hepatitis
C virus genotypes in Southern Brazil. Braz J Med Biol Res 29: 1629–32.
25. Galperim B, Cheinquer H, Stein A, Fonseca A, Lunge V, et al. (2006)
Prevalence of hepatitis C virus in alcoholic patients: role of parenteral risk
factors. Arq Gastroenterol 43: 81–84.
26. Garten RJ, Zhang J, Lai S, Liu W, Chen J, et al. (2005) Coinfection with HIV
and hepatitis C virus among injection drug users in southern China. Clin Infect
Dis 41 (S1): S18–24.
27. Rubio Caballero M, Rubio Rivas C, Nogues Biau A, Manonelles Fernandez A
(2005) Epidemiology of chronic hepatitis C virus in patients infected by human
immunodeficiency virus. Study of 767 patients. Med Clin (Barc) 125: 56–8.
28. Ramos B, Nunez M, Toro C, Sheldon J, Garcia-Samaniego J, et al. (2007)
Changes in the distribution of hepatitis C virus (HCV) genotypes over time in
Spain according to HIV serostatus: implications for HCV therapy in HCV/
HIV-coinfected patients. J Infect 54: 173–9.
29. Gonzalez SA, Liu RC, Edlin BR, Jacobson IM, Talal AH (2006) HIV/hepatitis
C virus-coinfected patients with normal alanine aminotransferase levels. J Acquir
Immune Defic Syndr 41: 582–9.
30. Zocratto KB, Caiaffa WT, Proietti FA, Carneiro-Proietti AB, Mingoti SA, et al.
(2006) HCV and HIV infection and co-infection: injecting drug use and sexual
behavior, AjUDE-Brasil I Project. Cad Saude Publica 22: 839–48.
31. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, et al. (2008)
EuroSIDA Study Group. Spontaneous viral clearance, viral load, and genotype
distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV
antibodies in Europe. J Infect Dis1: 1337–44.
32. Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, et al. (2004) HIV and
hepatitis C coinfection within the CAESAR study. HIV Med 5: 174–9.
33. Kubista M, Andrade JM, Bengtsson M, Forootan A, Jona ´k J, et al. (2006) The
real-time polymerase chain reaction. Mol Aspects Med 27: 95–125.
34. Kim AY, zur Wiesch JS, Kuntzen T (2006) Impaired hepatitis C virus-specific T
cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med 3:
e492.
35. Schott E, Witt H, Hinrichsen H, Neumann K, Weich V, et al. (2007) Gender-
dependent association of CTLA4 polymorphisms with resolution of hepatitis C
virus infection. J Hepatol 46: 372–80.
36. Folgori A, Spada E, Pezzanera M, Ruggeri L, Mele A, et al. (2006) Acute
Hepatitis C Italian Study Group. Early impairment of hepatitis C virus specific
T cell proliferation during acute infection leads to failure of viral clearance. Gut
55: 1012–9.
37. Busch MP, Glynn SA, Stramer SL, Orland J, Murphy EL, et al. (2006)
Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive
blood donors. Transfusion 46: 469–75.
38. Quinn PG, Jamal MM, Carey JD, Arora S, Harris T, et al. (1999) A case-control
study of the factors associated with spontaneous resolution of hepatitis C viremia.
Am J Gastroenterol 94: 668–73.
39. Karmochkine M, Carrat F, Dos Santos O, Cacoub P, Raguin G, et al. (2006) A
case-control study of risk factors for hepatitis C infection in patients with
unexplained routes of infection. J Viral Hepat 13: 775–82.
40. Hyder Q, Burhan-ul-Haq M, Rashid R, Qazi S, Mehmood S, et al. (2009) Non-
conventional transmission of hepatitis C: a true possibility ignored. J Pak Med
Assoc 59: 430–3.
HCV-HIV Co-Infection in Brazil
PLoS ONE | www.plosone.org 5 May 2010 | Volume 5 | Issue 5 | e1049441. Zylberberg H, Thiers V, Lagorce D, Squadrito G, Leone F, et al. (1999)
Epidemiological and virological analysis of couples infected with hepatitis C
virus. Gut 45: 112–6.
42. Lock G, Dirscher M, Obermeier F, Gelbmann CM, Hellerbrand C, et al. (2006)
Hepatitis C–contamination of toothbrushes: myth or reality? J Viral Hep 13:
571–3.
HCV-HIV Co-Infection in Brazil
PLoS ONE | www.plosone.org 6 May 2010 | Volume 5 | Issue 5 | e10494